Juho Jalkanen

Company: Faron Pharmaceuticals
Job title: Chief Operating Officer
Seminars:
Clinical Update on Bexmarilimab – the First-in-Class Anti-CLEVER-1 mAb 9:30 am
• FiH Phase I/II study showing extended survival in last line patients • Review biomarkers to identify responding patients • Outline future development plans based on the FiH Phase I/II resultsRead more
day: Day One